ASH: Study Identifies Less Toxic Combo for Multiple Myeloma
Publicado: Dom Dic 06, 2009 7:54 pm
ASH: Study Identifies Less Toxic Combo for Multiple Myeloma
By Ed Susman, Contributing Writer, MedPage Today
Published: December 05, 2009
Reviewed by Zalman S. Agus, MD; Emeritus Professor
University of Pennsylvania School of Medicine. Earn CME/CE credit
for reading medical news
Action Points
"NEW ORLEANS -- Results of a randomized trial comparing treatment regimens for elderly patients with multiple myeloma suggest treatment toxicity may be reduced without sacrificing efficacy if melphalan rather than thalidomide is paired with bortezomib (Velcade).
"In the melphalan group, there was more neutropenia and the possibility of infections," said Maria-Victoria Mateos, MD, PhD, attending physician in hematology at Hospital Universitario de Salamanca in Spain, but cardiac toxicity seen among patients receiving thalidomide in the combination therapy "was more difficult to treat."
By contrast, she said that neutropenia could be prevented or controlled with prophylactic treatments. Mateos discussed the findings during a press briefing at the American Society of Hematology meeting here.
But both regimens -- bortezomib/melphalan/prednisone or bortezomib/thalidomide/prednisone -- were effective."............
Leer mucho mas en:
http://www.medpagetoday.com/MeetingCove ... logy/17339
By Ed Susman, Contributing Writer, MedPage Today
Published: December 05, 2009
Reviewed by Zalman S. Agus, MD; Emeritus Professor
University of Pennsylvania School of Medicine. Earn CME/CE credit
for reading medical news
Action Points
"NEW ORLEANS -- Results of a randomized trial comparing treatment regimens for elderly patients with multiple myeloma suggest treatment toxicity may be reduced without sacrificing efficacy if melphalan rather than thalidomide is paired with bortezomib (Velcade).
"In the melphalan group, there was more neutropenia and the possibility of infections," said Maria-Victoria Mateos, MD, PhD, attending physician in hematology at Hospital Universitario de Salamanca in Spain, but cardiac toxicity seen among patients receiving thalidomide in the combination therapy "was more difficult to treat."
By contrast, she said that neutropenia could be prevented or controlled with prophylactic treatments. Mateos discussed the findings during a press briefing at the American Society of Hematology meeting here.
But both regimens -- bortezomib/melphalan/prednisone or bortezomib/thalidomide/prednisone -- were effective."............
Leer mucho mas en:
http://www.medpagetoday.com/MeetingCove ... logy/17339